Ross Stores vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Dublin CA largest US off-price retailer (NASDAQ: ROST) at $21.1B FY2024 sales (+3.7%), $2.1B net income; 2,273 stores expanding to 2,900 Ross + 700 dd's target competing with TJX Companies for off-price apparel shoppers.
About
Ross Stores, Inc. is a Dublin, California-based off-price variety retailer — publicly traded on NASDAQ (NASDAQ: ROST) as an S&P 500 Consumer Discretionary component — operating two retail banners: Ross Dress for Less (name-brand and designer apparel, footwear, and home fashion at 20-60% below department store prices) and dd's DISCOUNTS (20-70% below moderate department store prices for more budget-conscious shoppers) through approximately 107,000 employees. In fiscal year 2024, Ross Stores reported $21.1 billion in total sales (up 3.7% year-over-year), net earnings of $2.1 billion, and EPS of $6.32 (versus $5.56 in fiscal 2023), opening 89 new stores (75 Ross, 14 dd's) to end FY2024 with 2,205 total stores. As of 2025, Ross operates 2,273 stores across 44 states, Washington D.C., Guam, and Puerto Rico with long-term expansion targets of 2,900 Ross Dress for Less and 700 dd's DISCOUNTS locations. Founded in 1950 as a small department store chain in San Bruno, California, Ross transformed into an off-price retailer in 1982 under new management and grew into the largest US off-price retailer by revenue. The company sources merchandise through buying offices in New York City, Los Angeles, and Boston, accessing manufacturer overruns, retail liquidations, and closeout opportunities from thousands of vendors and brand partners. Seven distribution centers support the nationwide store network.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.